RG
Remko Griep
View Remko's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Senior Expert Antibody Biology
Jan 2021 - Sep 2023 · 2 years and 8 months
Senior Scientist
Feb 2019 - Mar 2019 · 1 months
Vice President New Antibody Technolgy And Head Of Qm And Compliance
Sep 2014 - Apr 2017 · 2 years and 7 months
Company Details
51-200 Employees
We are a rapidly growing and transformative food and crop protection company developing a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Based on our ground-breaking technology platform, Biotalys is developing a broad pipeline of effective and safe products with novel modes of action, addressing key crop pests and diseases across the whole value chain, from soil to plate. Biotalys’ unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. We are on track to launch our first biofungicide in the USA in H2 2022, followed by subsequent market introductions globally. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.
Year Founded
2013
Social Media
LinkedinTwitter
Industry
Biotechnology Research, Administration of Economic Programs, Public Administration
HQ Location
Buchtenstraat 11 Ghent, Flemish Region 9051, BE
Keywords
Food Protection and Crop Protectionsustainable foodfruit and vegetablecrop protection productstransform foodbiotech clusterprotein based cropfield and greenhousefungicide expectedfood and crop
Discover More About Cleveland Clinic

Find verified contacts of Remko Griep in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.